Considering Role of Probiotic on Respiratory Disease: Is Probiotic Possible to Treat COVID-19?
Abstract Background: COVID-19 is a new variant of the corona virus known as a pandemic disease. The number of cases has increased every day around the world. Unfortunately, treatment in management has not been satisfactory. Purpose: This study aims to examine the role of probiotics in respirator...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article PeerReviewed |
| Language: | English Indonesian English English |
| Published: |
Medico Publication
2021
|
| Subjects: | |
| Online Access: | https://repository.unair.ac.id/124462/1/19.%20Artikel%2080.pdf https://repository.unair.ac.id/124462/2/19.%20Karil.pdf https://repository.unair.ac.id/124462/3/19.%20Korespondensi.pdf https://repository.unair.ac.id/124462/4/19.turnitin.pdf https://repository.unair.ac.id/124462/ https://medicopublication.com/index.php/ijfmt/article/view/14998 https://doi.org/10.37506/ijfmt.v15i2.14998 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Universitas Airlangga |
| Language: | English Indonesian English English |
| Summary: | Abstract
Background: COVID-19 is a new variant of the corona virus known as a pandemic disease. The number
of cases has increased every day around the world. Unfortunately, treatment in management has not been
satisfactory.
Purpose: This study aims to examine the role of probiotics in respiratory disease and the possibility of
managing COVID-19 through an analysis of its function.
Method: This study is a review. Quality journals until 2020 were searched in the Pubmed database for
the keywords ‘respiratory’ or ‘asthma’ or ‘pneumonia’ or ‘lung’ or ‘influenza’ and ‘COVID-19’. Compiled
data includesthe author, type of study, type of probiotic, duration of intervention, target population, results,
conclusion and side effects that occurred
Results: We analyzed 9 experimental studies. Some studies related to respiratory disorders used the
Lactobacillus Sp as probiotic. One research used Fructooligosacharide as additional ingredient. The research
use different doses and timing of interventions 14 days - 6 months. The diseases covered in this report
are asthma, pneumonia, and influenza. Probiotics can reduce symptomps, duration in hospitality risk, and
quality of life.
Conclusion: The ability of probiotics in the management of respiratory diseases provides hope for the
management of COVID-19, of course, it is balanced with further research that is able to analyze clear
dosages, types and roles. |
|---|